Teva Pharmaceutical Industries (TEVA) institutional holders · P/E 91, rev $17.26B
Teva Pharmaceutical Industries institutional holders from SEC Form 13F, top 3 by reported value. Each row is the filer's newest 13F for quarters ended 2026-06-30 or later, share lines summed, options excluded; value is the 13F-reported market value in US dollars. Rows marked Prior quarter are filers whose 2026-09-30 13F is not cached yet.
| Holder | Shares | Value | Report |
|---|---|---|---|
| FMR LLC | 30,258,016 | $1.03B | 2026-06-30Prior quarter |
| STATE STREET CORP | 18,936,548 | $641.6M | 2026-06-30Prior quarter |
| Bridgewater Associates, LP | 1,326,678 | $44.9M | 2026-06-30Prior quarter |
TEVA institutional holders FAQ
What is TEVA's P/E ratio?
Teva Pharmaceutical Industries (TEVA) trailing P/E is 91.2 on the latest cached fundamentals snapshot.
What is TEVA's latest revenue?
Latest cached Teva Pharmaceutical Industries (TEVA) revenue for Dec 31, 2025 was $17.26B. Statements: https://lician.com/financials/teva
Not investment advice. Figures as filed or reported, not a live feed.